Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies

Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies

Friday, December 9, 2022 in New Orleans, LA
Live Meeting -- Sheraton New Orleans, 3:00 PM CT
Napoleon B 1-3 + Corridor A/B


  • Welcome and Introduction
  • Prognostic and Predictive Biomarkers for Risk Stratification and Treatment Selection for Patients with Aggressive B-Cell Lymphomas
    • Mantle-Cell Lymphoma (MCL)
    • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Selection and Sequencing of New and Emerging Agents Within the Patient Care Continuum
    • Different Classes of Agents and Differentiating Among Agents Within Each Class
    • Integrating Precision Medicine Approaches Into the Current Treatment Algorithm
    • Key Considerations for the Clinical Application of New and Emerging Data
  • Updated Management Algorithms for Patients with MCL and DLBCL
  • Clinical Trial Spotlight and Review of Key Data Presented at ASH 2022
  • Key Takeaways and Question and Answer Session


Program Director
John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

John Allan, MD

Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
Associate Editor, Blood
BC Cancer
Vancouver, BC

Program Overview
This program will provide expert faculty perspectives on the recent advances in precision medicine, including discussions of established and emerging treatment approaches regarding the new classes of agents and treatment regimens for patients with MCL and DLBCL, using clinical case studies to illustrate how to utilize prognostic and predictive biomarkers for risk stratification and for the selection and sequencing of therapy to achieve optimal safety and efficacy.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with MCL and DLBCL.

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with B‑cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Interpret expert-recommended molecular profiling for appropriate patients with MCL and DLBCL to guide therapy selection
  • Select treatment regimens for patients with MCL and DLBCL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with aggressive B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Plan optimal supportive care measures to manage adverse events associated with newer therapeutic regimens used in the treatment of MCL and DLBCL


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.